peptide analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
In 2013, during the Long Shutdown 1, three ISOLDE buildings were demolished. They've been built again as a new single building with a new control room, a data storage room, three laser laboratories, a biology and materials laboratory, and a room for visitors. Another building extension for the MEDICIS project and several others equipped with electrical, cooling and ventilation systems to be used for the HIE-ISOLDE project in the future were also built. In addition, the robots which were installed for the handling of radioactive targets have been replaced with more modern robots. In 2015, for the first time, a radioactive isotope beam could be accelerated to an energy level of 4.3 MeV per nucleon in the ISOLDE facility thanks to the HIE-ISOLDE upgrades. In late 2017, the CERN-MEDICIS facility produced its first radioisotopes and by the end of 2020 had provided external nine hospitals and research facilities with 41 batches of radioisotopes. Phase 2 of the facility's HIE-ISOLDE upgrade was completed in 2018, which allows ISOLDE to accelerate radioactive beams up to 10 MeV per nucleon.
When B cells and T cells are activated by a pathogen, memory B-cells and T- cells develop, and the primary immune response results. Throughout the lifetime of an animal, these memory cells will "remember" each specific pathogen encountered, and can mount a strong secondary response if the pathogen is detected again. The primary and secondary responses were first described in 1921 by English immunologist Alexander Glenny although the mechanism involved was not discovered until later. This type of immunity is both active and adaptive because the body's immune system prepares itself for future challenges. Active immunity often involves both the cell-mediated and humoral aspects of immunity as well as input from the innate immune system.
The light chain gene has three gene segments. These include: the light chain variable region (V), joining region (J), and constant region (C) gene segments. The variable region of light is therefore encoded by the rearrangement of VJ segments. The light chain can be either kappa,κ or lambda,λ. This process takes place at the level of mRNAs processing. Random rearrangements and recombinations of the gene segments at DNA level to form one kappa or lambda light chain occurs in an orderly fashion. As a result, "a functional variable region gene of a light chain contains two coding segments that are separated by a non-coding DNA sequence in unrearranged germ-line DNA".
77. Tirzepatide. Farzam K(1), Patel P. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2026 Sep 14. Author information: (1)McMaster University Tirzepatide is a medication approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea. As a dual agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, it improves glycemic control and reduces body weight in patients with type 2 diabetes. Administered once weekly via subcutaneous injection with incremental dose adjustments, tirzepatide is used as a second-line diabetes medication. Tirzepatide is not approved for the treatment of type 1 diabetes and has not been adequately studied in patients with pancreatitis. Common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhea. This activity provides an overview of the indications, mechanism of action, administration, adverse effects, contraindications, drug interactions, and considerations for specific patient populations. The activity also enhances clinicians’ competence in administering tirzepatide, monitoring treatment response and adverse effects, and managing patients with type 2 diabetes to improve patient outcomes and safety. Copyright © 2026, StatPearls Publishing LLC.
Sources: en.wikipedia.org
In 2024, Apple Inc. released Apple Vision Pro. This device features hardware such as dual panels that offer 24 million pixels, surpassing devices such as the Oculus Rift. The integration of the R1 chip, working in tandem with the M2 chip, results in a polling rate of 12 milliseconds, getting rid of the dizzying latency issues that were prevalent in previous devices.
Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
=== Gastropods === Achatina fulica, giant African snail (2019) Biomphalaria glabrata, a medically important air-breathing freshwater snail in the family Planorbidae (2017) Biomphalaria straminea, Ramshorn snail (2022) Candidula unifasciata, Land snail (2021) Conus ventricosus, Mediterranean cone snail (2021) Elysia chlorotica, a solar-powered sea slug (2019) Haliotis discus hannai, pacific abalone (2017) Kalloconus canariensis, Canary Island cone shell (2023) Kelletia kelletii, Kellet's whelk (2023) Lottia gigantea, owl limpet (2013) Plakobranchus ocellatus, Kleptoplastic sea slug (2021) Pomacea canaliculata, golden apple snail (2018) Littorina brevicula, periwinkle snail (2024) Littoraria sinensis (2024)
== Climbing experiences == In 1951, Gallwas began climbing with members of the Sierra Club from Southern California, including Royal Robbins and Don Wilson. The three became known as "The Southern Californians" to distinguish them from other California climbing groups. Gallwas described his relationship with Robbins and Wilson as teenage amateurs in tennis shoes. At Tahquitz (Lily Rock), the three honed their skills and dreamed of big climbs to come. The vision started to become a reality when, in 1953, the three made the second ascent of the North Wall of Sentinel Rock. Robbins showed little interest in desert climbing, so Gallwas teamed with Wilson and Mark Powell to make a series of pioneering first ascents of sandstone spires in the American Southwest. These included Spider Rock, Cleopatra's Needle, and the Totem Pole. Bill Feuerer joined Gallwas, Wilson, and Powell on the Totem Pole ascent. Gallwas' final major ascent was the Northwest Face of Half Dome in the summer of 1957. On this climb, he teamed with Royal Robbins and Mike Sherrick. The Regular Northwest Face of Half Dome ascent was the first Grade VI climb in the United States.
=== Mechanism of action === Enkephalins are peptides produced by the body that act on opioid receptors with preference for the δ subtype. Activation of δ receptors inhibits the enzyme adenylyl cyclase, decreasing intracellular levels of the messenger molecule cAMP. The active metabolite of racecadotril, thiorphan, inhibits enkephalinase enzymes in the intestinal epithelium with an IC50 of 6.1 nM, protecting enkephalins from being broken down by these enzymes. (Racecadotril itself is much less potent at 4500 nM.) This reduces diarrhea related hypersecretion in the small intestine without influencing basal secretion. Racecadotril also has no influence on the time substances, bacteria or virus particles stay in the intestine.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.